BREAKING
Encompass Health Corporation reports Q4 2025 results, issues 2026 guidance 2 days ago Graham Corporation Expands Capabilities Across Defense, Energy, and Space Markets 2 days ago Graham Corporation Sees Robust Q3 on Defense Momentum and FlackTek Integration 2 days ago Biogen’s Q4 FY25 adj. earnings decline, but beat estimates; revenue down 7% 2 days ago Infographic: How Philip Morris (PM) performed in Q4 2025 financial results 2 days ago Abbott reports positive results from study on its atrial fibrillation therapies 2 days ago Atmus Welcomes Heath Sharp to Board of Directors 2 days ago Cboe Global Markets Q4 2025 adj. earnings jump on record high revenues 2 days ago Zurn Elkay beats fourth quarter estimates, forecasts growth for 2026 4 days ago Yum China Reports Fourth Quarter and Full Year 2025 Financial Results 4 days ago Encompass Health Corporation reports Q4 2025 results, issues 2026 guidance 2 days ago Graham Corporation Expands Capabilities Across Defense, Energy, and Space Markets 2 days ago Graham Corporation Sees Robust Q3 on Defense Momentum and FlackTek Integration 2 days ago Biogen’s Q4 FY25 adj. earnings decline, but beat estimates; revenue down 7% 2 days ago Infographic: How Philip Morris (PM) performed in Q4 2025 financial results 2 days ago Abbott reports positive results from study on its atrial fibrillation therapies 2 days ago Atmus Welcomes Heath Sharp to Board of Directors 2 days ago Cboe Global Markets Q4 2025 adj. earnings jump on record high revenues 2 days ago Zurn Elkay beats fourth quarter estimates, forecasts growth for 2026 4 days ago Yum China Reports Fourth Quarter and Full Year 2025 Financial Results 4 days ago
ADVERTISEMENT

Abbott Laboratories (ABT) Earnings: 1Q21 Key Numbers

Abbott Laboratories (NYSE: ABT) reported first quarter 2021 earnings results today. Sales increased 35.3% year-over-year to $10.5 billion. On an organic basis, sales growth was 32.9%. On a GAAP basis, net earnings more than doubled to $1.79 billion, or $1.00 per share, compared to the year-ago period. Adjusted EPS jumped 103% to $1.32. For FY2021, […]

$ABT April 20, 2021 1 min read

Abbott Laboratories (NYSE: ABT) reported first quarter 2021 earnings results today.

Sales increased 35.3% year-over-year to $10.5 billion. On an organic basis, sales growth was 32.9%.

On a GAAP basis, net earnings more than doubled to $1.79 billion, or $1.00 per share, compared to the year-ago period. Adjusted EPS jumped 103% to $1.32.

For FY2021, Abbott projects GAAP EPS from continuing operations to be at least $3.74. Adjusted EPS from continuing operations is expected to be at least $5.00.

ADVERTISEMENT